These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 24696184)

  • 1. Combination treatment with theranostic nanoparticles for glioblastoma sensitization to TMZ.
    Yoo B; Ifediba MA; Ghosh S; Medarova Z; Moore A
    Mol Imaging Biol; 2014 Oct; 16(5):680-9. PubMed ID: 24696184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
    Carlson BL; Grogan PT; Mladek AC; Schroeder MA; Kitange GJ; Decker PA; Giannini C; Wu W; Ballman KA; James CD; Sarkaria JN
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):212-9. PubMed ID: 19695438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Redox-responsive magnetic nanoparticle for targeted convection-enhanced delivery of O6-benzylguanine to brain tumors.
    Stephen ZR; Kievit FM; Veiseh O; Chiarelli PA; Fang C; Wang K; Hatzinger SJ; Ellenbogen RG; Silber JR; Zhang M
    ACS Nano; 2014 Oct; 8(10):10383-95. PubMed ID: 25247850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temozolomide nanoparticles for targeted glioblastoma therapy.
    Fang C; Wang K; Stephen ZR; Mu Q; Kievit FM; Chiu DT; Press OW; Zhang M
    ACS Appl Mater Interfaces; 2015 Apr; 7(12):6674-82. PubMed ID: 25751368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted nitric oxide delivery preferentially induces glioma cell chemosensitivity via altered p53 and O(6) -methylguanine-DNA methyltransferase activity.
    Safdar S; Payne CA; Tu NH; Taite LJ
    Biotechnol Bioeng; 2013 Apr; 110(4):1211-20. PubMed ID: 23125026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
    Chung S; Sugimoto Y; Huang J; Zhang M
    ACS Appl Mater Interfaces; 2023 Jan; 15(1):106-119. PubMed ID: 36442077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.
    Agnihotri S; Gajadhar AS; Ternamian C; Gorlia T; Diefes KL; Mischel PS; Kelly J; McGown G; Thorncroft M; Carlson BL; Sarkaria JN; Margison GP; Aldape K; Hawkins C; Hegi M; Guha A
    J Clin Invest; 2012 Jan; 122(1):253-66. PubMed ID: 22156195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
    Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma.
    Xu H; Zhang Y; Li L; Ren Y; Qian F; Wang L; Ma H; Quan A; Liu H; Yu R
    Drug Deliv; 2023 Dec; 30(1):1-13. PubMed ID: 36579448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
    Chen Z; Wei X; Shen L; Zhu H; Zheng X
    Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
    Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
    Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
    Cen L; Carlson BL; Pokorny JL; Mladek AC; Grogan PT; Schroeder MA; Decker PA; Anderson SK; Giannini C; Wu W; Ballman KV; Kitange GJ; Sarkaria JN
    Neuro Oncol; 2013 Jun; 15(6):735-46. PubMed ID: 23479134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells.
    Kato T; Natsume A; Toda H; Iwamizu H; Sugita T; Hachisu R; Watanabe R; Yuki K; Motomura K; Bankiewicz K; Wakabayashi T
    Gene Ther; 2010 Nov; 17(11):1363-71. PubMed ID: 20520650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
    Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC
    Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
    Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
    Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo.
    Sita TL; Kouri FM; Hurley LA; Merkel TJ; Chalastanis A; May JL; Ghelfi ST; Cole LE; Cayton TC; Barnaby SN; Sprangers AJ; Savalia N; James CD; Lee A; Mirkin CA; Stegh AH
    Proc Natl Acad Sci U S A; 2017 Apr; 114(16):4129-4134. PubMed ID: 28373576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology.
    Viel T; Monfared P; Schelhaas S; Fricke IB; Kuhlmann MT; Fraefel C; Jacobs AH
    Mol Ther; 2013 Mar; 21(3):570-9. PubMed ID: 23319055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
    Minea RO; Duc TC; Swenson SD; Cho HY; Huang M; Hartman H; Hofman FM; Schönthal AH; Chen TC
    PLoS One; 2020; 15(9):e0238238. PubMed ID: 32881880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
    Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
    NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O
    Chang KY; Hsu TI; Hsu CC; Tsai SY; Liu JJ; Chou SW; Liu MS; Liou JP; Ko CY; Chen KY; Hung JJ; Chang WC; Chuang CK; Kao TJ; Chuang JY
    Redox Biol; 2017 Oct; 13():655-664. PubMed ID: 28822335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.